Cargando…

The role of brain natriuretic peptide in atrial fibrillation: a substudy of the Substrate Modification with Aggressive Blood Pressure Control for Atrial Fibrillation (SMAC-AF) trial

BACKGROUND: Catheter ablation is an established therapy for atrial fibrillation but is limited by recurrence; efforts have been made to identify biomarkers that predict recurrence. We investigated the effect of baseline NT-proBNP on AF recurrence following catheter ablation in patients randomized to...

Descripción completa

Detalles Bibliográficos
Autores principales: Weng, Willy, Choudhury, Rajin, Sapp, John, Tang, Anthony, Healey, Jeff S., Nault, Isabelle, Rivard, Lena, Greiss, Isabelle, Bernick, Jordan, Parkash, Ratika
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8447763/
https://www.ncbi.nlm.nih.gov/pubmed/34530738
http://dx.doi.org/10.1186/s12872-021-02254-5
_version_ 1784569086158569472
author Weng, Willy
Choudhury, Rajin
Sapp, John
Tang, Anthony
Healey, Jeff S.
Nault, Isabelle
Rivard, Lena
Greiss, Isabelle
Bernick, Jordan
Parkash, Ratika
author_facet Weng, Willy
Choudhury, Rajin
Sapp, John
Tang, Anthony
Healey, Jeff S.
Nault, Isabelle
Rivard, Lena
Greiss, Isabelle
Bernick, Jordan
Parkash, Ratika
author_sort Weng, Willy
collection PubMed
description BACKGROUND: Catheter ablation is an established therapy for atrial fibrillation but is limited by recurrence; efforts have been made to identify biomarkers that predict recurrence. We investigated the effect of baseline NT-proBNP on AF recurrence following catheter ablation in patients randomized to aggressive (< 120/80 mmHg) or standard blood pressure management (< 140/90 mmHg) in the Substrate Modification with Aggressive Blood Pressure Control trial (SMAC-AF). METHODS: The SMAC-AF study included 173 patients resistant or intolerant to at least one class I or III antiarrhythmic drug. We studied the effect of baseline NT-proBNP on the primary outcome of AF recurrence > 3 months post-ablation. RESULTS: Of the 173 patients, 88 were randomized to the aggressive cohort, and 85 into the standard group. The primary outcome occurred in 61.4% of those in the aggressive arm, versus 61.2% in the standard arm. In the aggressive group, logNT-proBNP predicted recurrence (HR 1.28, p = 0.04, adjusted HR 1.43, p = 0.03), while in the standard cohort, it did not (HR 0.94, p = 0.62, adjusted HR 0.83, p = 0.22). NT-proBNP ≥ 280 pg/mL also predicted occurrence in the aggressive (HR 1.98, p = 0.02) but not the standard cohort (HR 1.00, p = 1.00). CONCLUSION: We conclude that pre-ablation NT-proBNP may be useful in predicting recurrence in hypertensive patients and identifying patients who benefit from aggressive blood control and upstream therapies. Trial registration: NCT00438113, registered February 21, 2007.
format Online
Article
Text
id pubmed-8447763
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-84477632021-09-20 The role of brain natriuretic peptide in atrial fibrillation: a substudy of the Substrate Modification with Aggressive Blood Pressure Control for Atrial Fibrillation (SMAC-AF) trial Weng, Willy Choudhury, Rajin Sapp, John Tang, Anthony Healey, Jeff S. Nault, Isabelle Rivard, Lena Greiss, Isabelle Bernick, Jordan Parkash, Ratika BMC Cardiovasc Disord Research BACKGROUND: Catheter ablation is an established therapy for atrial fibrillation but is limited by recurrence; efforts have been made to identify biomarkers that predict recurrence. We investigated the effect of baseline NT-proBNP on AF recurrence following catheter ablation in patients randomized to aggressive (< 120/80 mmHg) or standard blood pressure management (< 140/90 mmHg) in the Substrate Modification with Aggressive Blood Pressure Control trial (SMAC-AF). METHODS: The SMAC-AF study included 173 patients resistant or intolerant to at least one class I or III antiarrhythmic drug. We studied the effect of baseline NT-proBNP on the primary outcome of AF recurrence > 3 months post-ablation. RESULTS: Of the 173 patients, 88 were randomized to the aggressive cohort, and 85 into the standard group. The primary outcome occurred in 61.4% of those in the aggressive arm, versus 61.2% in the standard arm. In the aggressive group, logNT-proBNP predicted recurrence (HR 1.28, p = 0.04, adjusted HR 1.43, p = 0.03), while in the standard cohort, it did not (HR 0.94, p = 0.62, adjusted HR 0.83, p = 0.22). NT-proBNP ≥ 280 pg/mL also predicted occurrence in the aggressive (HR 1.98, p = 0.02) but not the standard cohort (HR 1.00, p = 1.00). CONCLUSION: We conclude that pre-ablation NT-proBNP may be useful in predicting recurrence in hypertensive patients and identifying patients who benefit from aggressive blood control and upstream therapies. Trial registration: NCT00438113, registered February 21, 2007. BioMed Central 2021-09-16 /pmc/articles/PMC8447763/ /pubmed/34530738 http://dx.doi.org/10.1186/s12872-021-02254-5 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Weng, Willy
Choudhury, Rajin
Sapp, John
Tang, Anthony
Healey, Jeff S.
Nault, Isabelle
Rivard, Lena
Greiss, Isabelle
Bernick, Jordan
Parkash, Ratika
The role of brain natriuretic peptide in atrial fibrillation: a substudy of the Substrate Modification with Aggressive Blood Pressure Control for Atrial Fibrillation (SMAC-AF) trial
title The role of brain natriuretic peptide in atrial fibrillation: a substudy of the Substrate Modification with Aggressive Blood Pressure Control for Atrial Fibrillation (SMAC-AF) trial
title_full The role of brain natriuretic peptide in atrial fibrillation: a substudy of the Substrate Modification with Aggressive Blood Pressure Control for Atrial Fibrillation (SMAC-AF) trial
title_fullStr The role of brain natriuretic peptide in atrial fibrillation: a substudy of the Substrate Modification with Aggressive Blood Pressure Control for Atrial Fibrillation (SMAC-AF) trial
title_full_unstemmed The role of brain natriuretic peptide in atrial fibrillation: a substudy of the Substrate Modification with Aggressive Blood Pressure Control for Atrial Fibrillation (SMAC-AF) trial
title_short The role of brain natriuretic peptide in atrial fibrillation: a substudy of the Substrate Modification with Aggressive Blood Pressure Control for Atrial Fibrillation (SMAC-AF) trial
title_sort role of brain natriuretic peptide in atrial fibrillation: a substudy of the substrate modification with aggressive blood pressure control for atrial fibrillation (smac-af) trial
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8447763/
https://www.ncbi.nlm.nih.gov/pubmed/34530738
http://dx.doi.org/10.1186/s12872-021-02254-5
work_keys_str_mv AT wengwilly theroleofbrainnatriureticpeptideinatrialfibrillationasubstudyofthesubstratemodificationwithaggressivebloodpressurecontrolforatrialfibrillationsmacaftrial
AT choudhuryrajin theroleofbrainnatriureticpeptideinatrialfibrillationasubstudyofthesubstratemodificationwithaggressivebloodpressurecontrolforatrialfibrillationsmacaftrial
AT sappjohn theroleofbrainnatriureticpeptideinatrialfibrillationasubstudyofthesubstratemodificationwithaggressivebloodpressurecontrolforatrialfibrillationsmacaftrial
AT tanganthony theroleofbrainnatriureticpeptideinatrialfibrillationasubstudyofthesubstratemodificationwithaggressivebloodpressurecontrolforatrialfibrillationsmacaftrial
AT healeyjeffs theroleofbrainnatriureticpeptideinatrialfibrillationasubstudyofthesubstratemodificationwithaggressivebloodpressurecontrolforatrialfibrillationsmacaftrial
AT naultisabelle theroleofbrainnatriureticpeptideinatrialfibrillationasubstudyofthesubstratemodificationwithaggressivebloodpressurecontrolforatrialfibrillationsmacaftrial
AT rivardlena theroleofbrainnatriureticpeptideinatrialfibrillationasubstudyofthesubstratemodificationwithaggressivebloodpressurecontrolforatrialfibrillationsmacaftrial
AT greissisabelle theroleofbrainnatriureticpeptideinatrialfibrillationasubstudyofthesubstratemodificationwithaggressivebloodpressurecontrolforatrialfibrillationsmacaftrial
AT bernickjordan theroleofbrainnatriureticpeptideinatrialfibrillationasubstudyofthesubstratemodificationwithaggressivebloodpressurecontrolforatrialfibrillationsmacaftrial
AT parkashratika theroleofbrainnatriureticpeptideinatrialfibrillationasubstudyofthesubstratemodificationwithaggressivebloodpressurecontrolforatrialfibrillationsmacaftrial
AT wengwilly roleofbrainnatriureticpeptideinatrialfibrillationasubstudyofthesubstratemodificationwithaggressivebloodpressurecontrolforatrialfibrillationsmacaftrial
AT choudhuryrajin roleofbrainnatriureticpeptideinatrialfibrillationasubstudyofthesubstratemodificationwithaggressivebloodpressurecontrolforatrialfibrillationsmacaftrial
AT sappjohn roleofbrainnatriureticpeptideinatrialfibrillationasubstudyofthesubstratemodificationwithaggressivebloodpressurecontrolforatrialfibrillationsmacaftrial
AT tanganthony roleofbrainnatriureticpeptideinatrialfibrillationasubstudyofthesubstratemodificationwithaggressivebloodpressurecontrolforatrialfibrillationsmacaftrial
AT healeyjeffs roleofbrainnatriureticpeptideinatrialfibrillationasubstudyofthesubstratemodificationwithaggressivebloodpressurecontrolforatrialfibrillationsmacaftrial
AT naultisabelle roleofbrainnatriureticpeptideinatrialfibrillationasubstudyofthesubstratemodificationwithaggressivebloodpressurecontrolforatrialfibrillationsmacaftrial
AT rivardlena roleofbrainnatriureticpeptideinatrialfibrillationasubstudyofthesubstratemodificationwithaggressivebloodpressurecontrolforatrialfibrillationsmacaftrial
AT greissisabelle roleofbrainnatriureticpeptideinatrialfibrillationasubstudyofthesubstratemodificationwithaggressivebloodpressurecontrolforatrialfibrillationsmacaftrial
AT bernickjordan roleofbrainnatriureticpeptideinatrialfibrillationasubstudyofthesubstratemodificationwithaggressivebloodpressurecontrolforatrialfibrillationsmacaftrial
AT parkashratika roleofbrainnatriureticpeptideinatrialfibrillationasubstudyofthesubstratemodificationwithaggressivebloodpressurecontrolforatrialfibrillationsmacaftrial